OTC traders are being introduced to the newest penny stock that is focused on a state-of-the-art diabetes management platform that connects the user, caregiver and healthcare professional anywhere on the planet. Shares of LabStyle Innovations Corp. (DRIO) have been having a very good week thus far and now that the team James Connelly and Penny Stocks Prophet are making it known that they are bullish about it, attention is sure to increase. Although DRIO stock is currently priced well above the $1 level that most traders try to avoid, the Company is looking for much bigger pockets to dig into as they make their presence known at the 3rd Annual Marcum Microcap Conference later on today.
Our Next Pick Is Coming Soon!
Click HERE To Make Sure You Don’t Miss Any Of Our Hot Penny Stock Alerts!
DRIO Stock Quote
Market Cap: 38.81M
Last: 1.69 ▲ +0.07 (+4.32%)
Dollar Volume: $141,030
14-Day RSI: 63.07%
1st Resistance Point: 1.74
1st Support Level: 1.63
52Wk High: 3.10
52Wk Low: 1.282
LabStyle Innovations’ Dario™ tiny, handheld device is the kind of product that today’s glucose monitoring marketplace can really grab hold of. With the increased capabilities that the wireless world has to offer, innovations like this whereas the Dario™ carries a cartridge with up to 25 strips that lance the skin is easily uploadable to the Company’s cloud-based software with a smartphone to let the a user record, save, track, analyze, manage & share all their diabetes related information in one lifestyle management platform.
While LabStyle Innovations did just report to have an abundance of cash on hand, $3.812 million, as of March 31, 2014 which should be adequate to cover their expenses for Q2, the Company is on a presentation campaign at present with their visit to the Grand Hyatt Hotel in N.Y.C. today just one of many stops. The Company met with CRT Capital earlier in the month and was given a $7.24 price target from SeeThruEquity as they embark on the estimated $12Bn global demand for diabetic self-monitoring of blood glucose.
Interestingly, LabStyle Innvovations recently amended their S-1 to allow for the sale of up to a potential aggregate of 3,897,172 shares of DRIO stock by existing shareholders. However, assuming the Dario™ does become a household name for the glucose testing market, expansion into potentially dozens of other laboratory tests of bodily fluids like blood, urine and saliva could have a significant impact on DRIO stock down the road since their is a huge market for testing blood coagulation and cholesterol, as well as HIV.
From the look of things after scanning the SEC filings, DRIO stock appears to be on the up-and-up with no shady convertible note payable holders or any real toxic financiers behind their private placements. What will be interesting to see is if the Company can book revenues in Q2 and the remaining quarters of 2014 after having just begun shipping the Dario™ in March, 2014 to limited markets.
Looking for the Best Penny Stocks to Buy?
Click HERE To Receive FREE Penny Stock Alerts
About DRIO Stock
LabStyle Innovations Corp. is a development stage mobile health company developing and commercializing patent-pending technology providing consumers with laboratory-testing capabilities using smart phones and other mobile devices.
Issued and Outstanding: 22,966,389
Last 5 Trading Sessions:
mHealth gadgets like the Dario™ are a dime a dozen, but the ones that truly fit the niche that they go after can really become massive provided they do work as they are supposed to. With the limited range that DRIO shares have traded in over the past 2 months, expecting it to be a breakout penny stock is the wrong approach to take. Manufacturing is sure to become a financial burden should the product line kick off which means the bottom line numbers will constrain DRIO stock from reaching anytime soon that $7.24 price target they were given.